* Higher ed flexibility legislation moves forward
   
* Benson, Faculty Council talk non-monetary compensation at meeting
   
* Benefits rates, online open enrollment will be available Thursday
   
* Workshops explain shift in thinking about fundraising
   
* Boulder campus gets Googled for mapping project
   
* Regents name recipients of honorary degrees for 2010
   
* Five questions for Steve Lekson
   
* Symposium to examine personalized medicine, biotech advances
   
* Muller-Sievers named director of Center for Humanities and the Arts
   
* People
   
* Did you know...
   
* Letters to the Editor
   
* Guest Column: Understanding political, philosophical and intellectual diversity
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Faculty, students to chase tornadoes again this spring
 
  UCCS
  Educator to speak on U.S. security at National Press Club
 
  UC DENVER
  Program transforms schoolyards into farm land serving school, community
 
  ANSCHUTZ MEDICAL CAMPUS
  Breakthrough treatment extends lives of prostate cancer patients
 
  CU FOUNDATION
  CU-Boulder freshman campaigns for scholarship in memory of friends
 
  TECH TRANSFER
  Biotech company expands Alzheimer's disease partnership with CU
 
   Home
   Newsletter Archive
 
 
Download Newsleter in PDF
 
Share your thoughts
  LETTERS TO THE EDITOR
Share your opinions

CONTACT US
Send your thoughts and suggestions for the Newsletter
   
   
   
   
   
   
   
   

News from the CU system - Anschutz Medical Campus

Breakthrough treatment extends lives of prostate cancer patients

The Food and Drug Administration has approved an immune therapy against prostate cancer, a major breakthrough that will extend the lives of many advanced-stage prostate cancer patients.

Dendreon, the company that manufactures the activated immune therapy called Provenge, says only a few patients will be able to get the treatment in the next 12 months while manufacturing gets up to full speed. The treatment will be available at the University of Colorado Hospital.

"Years of research have provided evidence that the immune system fights cancer, but this is the first time an immune-therapy approach has received FDA approval with a large-scale clinical trial," said L. Michael Glodé, Robert Rifkin chair of prostate cancer research at the University of Colorado School of Medicine and associate director of the outreach program at the University of Colorado Cancer Center. "Unfortunately, the availability of the therapy will be limited at first while the company opens new manufacturing facilities. Initially, we expect to treat one to three patients a month. The issues with the manufacturer should be resolved in about a year."

Provenge trains the body's immune system to attack cancer cells. The therapy involves removing white blood cells from the patient through a process called apheresis and then mixing the cells with a drug designed to stimulate the emergence of target specific cancer cells. The treated blood is then infused back into the patient. A large number of patients involved in the research that lead to the approval of this immune therapy have been treated at University of Colorado Hospital.

"This vaccine could form the basis for optimism that we can finally develop better immunologic treatments for common cancers, including prostate cancer," said Thomas Flaig, M.D., assistant professor in medical oncology at the University of Colorado School of Medicine and member of the therapeutic development program at the University of Colorado Cancer Center. During clinical trials, the therapy extended the lives of advanced stage prostate cancer patients who have progressed despite hormone therapy by a median of four months. Three-year survival rates are also better in those who received Provenge in the clinical trial compared with those receiving the placebo.

More than 192,000 men are diagnosed with prostate cancer each year; 27,000 of them die. Prostate cancer is the third most common cause of death from cancer in men of all ages and is the most common cause of death from cancer in men over age 75. It is rarely found in men younger than 40.

Provenge will be available at University of Colorado Hospital. For more information about the innovative immune therapy, call 720-848-4500 or go to www.uch.edu/provenge.

Bookmark - Print - Share

 
Previous Anschutz Medical Campus Stories

04/28/2010
Some pediatric brain tumors might be worsened by immune gene expression

04/21/2010
School of Medicine, partners will work to prevent mistreatment of children

04/14/2010
University of Colorado Hospital provides funding for new crisis services system

04/07/2010
University of Colorado Cancer Center researchers receive $3.5 million grant

03/31/2010
Hospital receives distinguished designation for excellence in nursing

03/24/2010
Regional stem-cell center launched by School of Medicine

03/17/2010
School of Medicine program receives oral health grant

03/10/2010
UC Denver one of top places for postdocs to work

03/03/2010
University of Colorado Hospital internal medicine, specialty clinic relocating

02/24/2010
New type of complex genetic variation discovered

02/17/2010
UC Denver announces state's first bioengineering department

02/10/2010
School of Dental Medicine gives kids a smile

02/03/2010
Emergency medicine physicians take part in suicide research trial

01/27/2010
Researchers receive grant to study impact of law on public health practice

01/20/2010
Assembling planet's Tree of Life less daunting thanks to researchers

01/13/2010
State-of-the-art imaging offers enhanced treatment for arrhythmia

01/06/2010
Rural medicine, Down syndrome programs receive federal support

12/16/2009
Study highlights lack of knowledge regarding hospital medications

12/09/2009
School of Pharmacy researcher receives funding from Michael J. Fox Foundation

12/02/2009
New UC Denver program puts high school grads on pathway to med school

11/18/2009
Award of $577,000 will aid study of tuberculosis treatment

11/11/2009
Depression Center works to establish national network

11/04/2009
School of Medicine to take part in nationwide study of blood pressure

10/28/2009
College of Nursing expands offerings in Western Regional Graduate Program

10/21/2009
Study: Tanning associated with moles in very light-skinned children

10/14/2009
When the laboratory meets the studio

10/07/2009
When the laboratory meets the studio

09/30/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/23/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/16/2009
University of Colorado Cancer Center wins National Cancer Institute grant

09/02/2009
Ground broken on planned VA medical center

08/19/2009
SOM, state labor department to manage training facility

08/06/2009
Pulmonary hypertension drug helps former smokers

07/23/2009
Breast cancer researcher receives gift from Avon